Ads
    Related paper
  1. Out-of-pocket costs analysis of ifosfamide, epirubicin, and etoposide (IEV) and etoposide, solu-medrol-methylprednisolone, high-dose ara-C-cytarabine, and platinol-cisplatin (ESHAP) regimens in the patients with relapsed and refractory lymphoma in Iran
  2. Are Fludarabine Based Regimens Still Adequate for Relapsed/Refractory Follicular Lymphoma? An 18-Year Single-Center Experience
  3. Central Retinal Artery Occlusion during Cisplatin and Etoposide Chemotherapy for Small Cell Lung Cancer
  4. Gemcitabine-Capecitabine Chemotherapy Plus Intra-Arterial Epirubicin-Cisplatin in Pancreatic Cancer Patients after FOLFIRINOX First Line Chemotherapy: A Retrospective Analysis
  5. HIGH-DOSE CYTARABINE IN ACUTE MYELOID LEUKEMIA TREATMENT: A SYSTEMATIC REVIEW
  6. Development, Optimization and In vitro Evaluation of Etoposide loaded Lipid Polymer Hybrid Nanoparticles for controlled Drug Delivery on Lung Cancer
  7. A Preliminary Phase-2 Study with very High-Dose of Melatonin (1000 mg/day) in Untreatable Advanced Cancer Patients Already Progression on Previous Palliative Therapy with High-Dose Melatonin
  8. High-Dose Diuretic as Treatment of Refractory Ascites Compared with Paracentesis: An Evidence Based Case Report
  9. Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
  10. Re-Engraftment of Prior Cord Blood Graft in a Patient with Relapsed/Refractory Acute Myeloid Leukaemia following Haploidentical Transplantation